Introduction
It is well established that active epilepsy may have a negative impact on quality of life (QOL). Important influences are whether the epilepsy remains active, progresses or remits. 1 In patients with active epilepsy, symptoms of depression and seizure worry have been found to be of particular importance with regard to QOL. 2 However, for most patients, epilepsy is a relatively benign condition and about 70% become seizure-free, either without medication or following pharmacological treatment. 3 Most studies of QOL in seizure-free epilepsy patients suggest normal or nearnormal function with regard to general health profile, social activity, educational level, employment rate, neuropsychological function and behavioral adjustment. [4] [5] [6] [7] Schachter 8 argues that QOL for patients with epilepsy is determined by more than seizure control and he points to the important factors for QOL like mood disorders, stigma, seizure worry, self-esteem and self-mastery. In line with this some recent studies of seizure-free patients have found impaired QOL. These studies report the reduction in overall QOL, in social and physical function, in symptoms of depression, health concerns and low self-esteem, in a higher proportion of patients than would normally be expected. 7, 9, 10 In one recent study 103 patients on monotherapy, seizure-free for at least 1 year, completed questionnaires on demographic and clinical data, QOL and subjective experience of antiepileptic (AED) drug side effects. 29 The study found that subjective experience of treatment side effects and unemployment were the only significant predictors of poor overall QOL. The finding that side effects of AED monotherapy predicts poor quality of life does not match well with the results of a recently published study that found no significant improvement in QOL after AED-withdrawal in seizure free patients on monotherapy. 12 Neither do the results correspond to the findings of another new study of behavioral consequences of AED-withdrawal in seizure free patients, were only very slight improvement in mood and irritability was found. 30 On this background, the possible relation of AED monotherapy and poor QOL seems to be uncertain. To our knowledge previous studies on QOL in well-controlled epilepsy have not investigated determinants for QOL from a database that includes a wide range of health related and epilepsy related variables, as well as demographical data, neuropsychological data, data from a comprehensive personality inventory and results from a QOL-questionnaire. Thus, the aim of this study was to analyze predictors of QOL based on such a range of variables. The Quality of Life in Epilepsy-89 (QOLIE-89) 11 is a common measure of QOL, and
Based on the findings of previous studies of determinants of quality of life both in active and seizure-free epilepsy, we hypothesized that symptoms of depression, significant health concerns and unemployment/disability benefit would be the most important factors affecting QOL in patients with well-controlled epilepsy.
Methods

Patients
The patients described in the present paper were participants in a large study investigating the withdrawal of AEDs in seizure-free epilepsy patients on monotherapy. They were selected on basis of clinical criteria from the epilepsy registry at the Akershus University Hospital and from six neurological outpatient clinics in the Oslo area: they should have a diagnosis of epilepsy (at least two unprovoked seizures), be between 18 and 67 years old and seizure free on monotherapy for at least 2 years at the time of inclusion. Excluded patients were with: juvenile myoclonus epilepsy (JME), poly-pharmacy, paroxysmal epileptiform activity in patients with primarily generalised epilepsy, mental retardation, two prior withdrawal attempts, pregnant or seeking pregnancy, progressive neurological disease, other serious disease which may influence the health status of the patient in the study period and co-medication. Initially, 241 patients appeared to fulfil the inclusion criteria and were invited to participate in the study. A total of 83 (34%) patients were not eligible, either based on exclusion criteria or because they declined to participate. As many as 32 (13%) patients declined to participate. This rather large number must be viewed on the background that the study was part of a withdrawal study of AEDs, and many patients did not want to participate due to fear of seizure relapse. The remaining 158 patients underwent a neurological exam, a neuropsychological assessment and answered the QOLIE-89. A total of 126 (80%) agreed to answer the Minnesota Multiphasic Personality Inventory-2 (MMPI-2). 13 
Tests
A total of 13 neuropsychological tests, 2 subscales from the MMPI-2 and the overall score from QOLIE-89 were employed: 5. Motor coordination: motor speed and complex coordination was measured by the Grooved Pegboard Test. 22 6. Depression and health concerns: depression and health concerns were assessed with two subscales (D and HEA) from the Norwegian Edition of MMPI-2. 13, 23 Norwegian normative data were used to score data from the MMPI-2. 23 Definition of abnormal function was T-scores equal to or greater than 65 on the different subscales. 7. Quality of life: the Quality of Life in Epilepsy-89 was developed in the United States (QOLIE-89). 11 Several content scores can be derived but the most common summary measure is the overall QOLIE-89 score, which was chosen as the outcome measure in this study. The reliability and validity of the Norwegian version of the QOLIE-89 has been confirmed in a study by Stavem et al. 24 All the test results were converted to T-scores, a normally distributed scale with a mean score of 50 and standard deviation (SD) of 10.
Statistical analysis
Statistical analyses were performed with the Statistical Package for Social Sciences for Windows (SPSS, version 12.0). First, descriptive statistics of the demographic, clinical and behavioral characteristics of the patient population were computed. To assess possible predictors of poor QOL we tested variables of importance in a logistic univariate model. QOL was dichotomised, with the categories normal (T 40) and subnormal (T 39) as the dependent variable. The independent variables included MRI pathology, known etiology, epileptiform activity on EEG, presence of GTCS, presence of IGE, complex partial seizures, epilepsy onset at age <18 years, duration of seizure freedom >5 years, AED within therapeutic range, AED above median serum level, pathological neurological exam, neuropsychological impairment, unemployment/disability benefit, pathological MMPI-2 Depression Scale (D) (T 65) and pathological MMPI-2 Health Concerns (HEA) Scale (T 65). Definition of impaired neuropsychological function was 2 or more out of 13 test results with T-scores equal to or below 30. 31 Because only 14 events occurred, the number of variables in the final multivariate analysis was limited to three (HEA scale T 65, unemployment/disability benefit, D-scale T 65).
Results
Demographical and clinical data
Demographic data and clinical information of the 158 study patients are presented in Table 1 . There were no demographic differences between the 158 patients that both underwent neuropsychological assessment and answered the QOLIE-89, and the 126 patients that answered the MMPI-2. Overall QOLIE-89 14 (9) score was similar between the two groups. Neuropsychological function of the study patients has been described previously. 6 The group achieved their poorest performance on the COWA (T = 42.1), the Choice Reaction Time Base (T = 44.8) and Choice Reaction Time Lexical (T = 43.2) whereas the remaining scores are close to T = 50 (Table 2) . Impaired neuropsychological function, defined as two or more T-scores 30 (from a total of 13 tests), was evident in 35 (22%) patients (Table 1 ). An analysis of the behavioral function of the patient group has recently been described by Hessen et al. 7 The mean T-scores on the subscales from the MMPI-2, hypothesized to predict poor QOL, were close to one standard deviation above the normative mean: Depression (D) (T = 59.0) and HEA (T = 58.7) ( Table 2 ).
Quality of life
The mean group score on the QOLIE-89 was almost 5 T-scores above the normative mean (T = 54.8) ( Table 2 ). Subnormal QOLIE-89 score defined as T 39 was evident in 14 (9%) of the patients (Table 1) .
Prediction of quality of life
Univariate regression analysis revealed significant association between subnormal QOLIE-89 score and patients with substantial health concerns, patients unemployed/on disability benefit and patients with depression (Table 3) . However, multiple regression analysis showed that a pathological score on the MMPI-2 Health Concerns scale was the only significant predictor of poor quality of life (OR = 10.76, p = 0.007).
Discussion
The main findings of the present study were that (i) QOL in wellcontrolled epilepsy patients was in the normal range and that (ii) presence of substantial health concerns and worries was a significant predictor of poor quality of life.
To our knowledge previous studies of QOL in well-controlled epilepsy have not been able to investigate determinants for QOL from a database that in addition to include a wide range of health related and epilepsy related variables, as well as demographical data, data from a comprehensive personality inventory also included neuropsychological data.
There is reason to believe that the patients participating in this study are representative of the majority of well-controlled epilepsy patients. 3, 25 However, the findings are not valid for all seizure-free epilepsy patients, as persons with poly-pharmacy, 26 paroxysmal epileptiform activity with primarily generalised epilepsy, 27 mental retardation, and progressive neurological disease were excluded from the study. The mean group score on the overall QOLIE-89 was 4.8 T-scores higher than the normative mean reported in the US. 11 The US normative data are based on a sample of 304 persons from 25 epilepsy centers. Of these only 21 (7%) had been seizure free for the last 12 months. Thus, in our sample of patients with less severe epilepsy, seizure-free for 2 years or more, we would expect better QOL and higher mean group scores. Based on multivariate regression analysis, subnormal overall QOLIE-89 score was only predicted by presence of abnormally high score on the HEA scale from the MMPI-2. High scorers on the HEA scale believe they are experiencing poor health, worry about their health and often report a variety of neurological and gastrointestinal symptoms. 28 The finding that considerable health concerns predicts poor QOL may compare well with Table 2 Test results expressed as T-scores.
Neuropsychological tests
Mean T-scores all study patients (SD) n = 158 findings in patients with active epilepsy where an important health concern -seizure worry -have been found to be of particular importance. 2 In the same study of active epilepsy, Loring et al. found that depression also was an important predictor of poor QOL. Univariate analysis in the present study indicated an association of high depression score on the MMPI-2 and poor OQL. Another study of predictors of QOL in seizure-free epilepsy patients 29 found that unemployment was a significant predictor of poor overall QOL. Univariate analysis in the present study also indicated an association of a similar variableunemployment/disability benefit -and poor OQL. However, mulitivariate regression revealed that none of these associations were strong enough to be significant. The finding of the present study of mean group score on the QOLIE-89 in the normal range compares well with results from other studies of QOL in well-controlled epilepsy patients. In a large study Jacoby 4 found minimal dysfunction with regard to energy, emotion, sleep, social isolation, physical mobility and stigmatisation, in patients seizure-free for at least 2 years. Additionally employment rates were close to normal. In a Norwegian study Stavem et al. 5 compared the health status of people with epilepsy with a general reference population. They found that 70% were seizure free for 1 year or more and that these had QOL-scores (SF-36) close to those of the general population. Hessen et al. 6 found, in a large group of adult patients, seizure free for at least 2 years on AED monotherapy, that neuropsychological function was in the normal range, and that education level and employment status were as normally expected in Norway. In another study by Hessen et al. 7 of patients seizure-free for more than 2 years, group analysis revealed that behavioral adjustment as measured with the Minnesota Multiphasic Personality Inventory-2 (MMPI-2), was in the normal range. However, some recent studies support the findings of the present study and indicate that aspects of QOL in some seizurefree patients may be poorer than normally expected. In the study by Hessen et al., 7 abnormally elevated scores on the MMPI-2 were recorded on scales of depression, health-related concerns, low self-esteem, negative treatment indicators, and physical complaints, in a higher proportion of patients than would normally be expected. Multiple regression analysis showed that MRI pathology was a significant predictor for low self-esteem, and that epilepsy onset 18 years was a significant predictor of poor work capability. These findings may be in line with the results from a study by Kobau et al., 10 where persons without seizures the last 3 months reported impaired quality of life. However, this result may be caused by the narrower definition of seizure freedom than that employed in other studies on seizure free patients. One smaller study 9 seem to support the two latter studies, in that they find clear reduction in social and physical function, when persons with well-controlled epilepsy were compared to healthy controls. Although QOL in well-controlled epilepsy predominantly is comparable to the general population, the latter studies indicate that aspects of QOL in seizure-free patients may be poorer than normally expected. The finding that the presence of substantial health concerns is a significant predictor of subnormal QOL in the common, seizurefree, epilepsy patient may have clinical implications. Studies have shown that for most patients that achieve seizure-freedom, either without medication or following pharmacological treatment, epilepsy is a relatively benign condition 3 with only minimal health problems. 4, 5 Second to treatment of the epilepsy, an essential clinical aim is to improve the QOL of the patients. Based on the knowledge that patients with substantial health concerns are at risk of poor QOL, there ought to be a clear opportunity for improvement of QOL in these patients, through careful information and counselling about the relatively benign condition that wellcontrolled epilepsy is.
In conclusion, the main findings of the present study were that QOL in well-controlled epilepsy patients was in the normal range and that presence of substantial health concerns and worries was a significant predictor of poor quality of life. The findings may have clinical implications, as seizure-free epilepsy is a relatively benign condition, and careful information and counselling about this may alleviate health concerns and improve quality of life.
